Boston Therapeutics (OTCMKTS:BTHE) and Neptune Wellness Solutions (NASDAQ:NEPT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation and institutional ownership.
This is a breakdown of recent recommendations for Boston Therapeutics and Neptune Wellness Solutions, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Neptune Wellness Solutions||0||0||1||0||3.00|
Earnings and Valuation
This table compares Boston Therapeutics and Neptune Wellness Solutions’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Boston Therapeutics||$20,000.00||87.24||-$3.69 million||N/A||N/A|
|Neptune Wellness Solutions||$22.05 million||8.86||-$45.76 million||($0.43)||-2.74|
Boston Therapeutics has higher earnings, but lower revenue than Neptune Wellness Solutions.
Insider & Institutional Ownership
17.2% of Neptune Wellness Solutions shares are owned by institutional investors. 15.7% of Boston Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility and Risk
Boston Therapeutics has a beta of -0.16, indicating that its share price is 116% less volatile than the S&P 500. Comparatively, Neptune Wellness Solutions has a beta of 2.43, indicating that its share price is 143% more volatile than the S&P 500.
This table compares Boston Therapeutics and Neptune Wellness Solutions’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Neptune Wellness Solutions||-97.35%||-46.39%||-37.77%|
Neptune Wellness Solutions beats Boston Therapeutics on 7 of the 12 factors compared between the two stocks.
About Boston Therapeutics
Boston Therapeutics, Inc., a pre-clinical and clinical-stage pharmaceutical development company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements in the United States. Its lead pharmaceutical drug candidates are BTI-320, a non-systemic carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic and pre diabetic patients; BTI-410, a peptide injectable compound that has completed Phase Ib clinical trials for type 1 immunosuppression therapy after kidney transplant surgery and type 2 diabetes patients; and IPOXYN, a carbohydrate-based injectable drug to prevent necrosis, or cell death, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. The company also produces and sells SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement to support healthy post-meal blood glucose. The company was formerly known as Avanyx Therapeutics, Inc. and changed its name to Boston Therapeutics, Inc. in November 2010. Boston Therapeutics, Inc. was founded in 2009 and is headquartered in Lawrence, Massachusetts.
About Neptune Wellness Solutions
Neptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada.
Receive News & Ratings for Boston Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.